Dendritic Cell News and Research RSS Feed - Dendritic Cell News and Research

Dendritic Cells are a special type of immune cell that is found in tissues, such as the skin, and boosts immune responses by showing antigens on its surface to other cells of the immune system. A dendritic cell is a type of phagocyte and a type of antigen-presenting cell (APC).
Three medical oncologists to receive ESMO's acclaimed awards

Three medical oncologists to receive ESMO's acclaimed awards

The European Society for Medical Oncology, the leading European professional organisation for advancing medical oncology, announced today the three exceptional medical oncologists who will receive its acclaimed awards. [More]
NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

NW Bio's DCVax-L Phase III trial ongoing for treatment of patients with newly diagnosed GBM

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. [More]
Study sheds light on helper cells and killer cells

Study sheds light on helper cells and killer cells

Scientists at the University of Bonn, together with colleagues from the USA and Japan, have shed light on an important immune mechanism. Their work shows how the body provides the important killer cells with a helper in the case of an infection. The study could point the way to better vaccines in the future. [More]
ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular signs agreement with FDA for phase 3 registrational trial of cancer immunotherapy ICT-107

ImmunoCellular Therapeutics, Ltd. announced today that it has reached agreement with the US Food and Drug Administration on a Special Protocol Assessment (SPA) for the phase 3 registrational trial of its cancer immunotherapy ICT-107 to treat patients with newly diagnosed glioblastoma. [More]
CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

CRI to honor three scientists for contributions to immunology and cancer immunotherapy research

The Cancer Research Institute, a nonprofit organization dedicated to fueling the discovery and development of immunotherapies for all forms of cancer, will bestow its highest honors on three scientists who have made fundamental contributions to the fields of immunology and cancer immunotherapy. [More]
ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular, Novella partner to conduct ICT-107 phase 3 registration trial in patients with glioblastoma

ImmunoCellular Therapeutics, Ltd. today announced the establishment of an agreement with Novella Clinical (Novella), to conduct the phase 3 registration trial of ICT-107 in patients with newly diagnosed glioblastoma. Novella is a full-service, global clinical research organization (CRO) providing clinical trial services to small to mid-sized oncology companies. [More]
Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics added to Russell indexes

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced that it has been added to the Russell 2000, Russell 3000, Russell Global and Russell Microcap indexes following Russell Investments' ("Russell") reconstitution of its comprehensive set of U.S. and global equity indexes after the close of the U.S. markets on June 26, 2015. [More]
Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

Pan Am Cancer Treatment Center announces publication of immuno-oncology text book

The Pan Am Cancer Treatment Center is pleased to announce the publication of a specialized textbook titled "Immuno-Oncology, from Bench to Bedside" which provides scientific rationale for the use of immunotherapy in the treatment of cancer. [More]
ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular, Pure MHC partner to develop new assay for ICT-107 phase 3 registrational clinical program

ImmunoCellular Therapeutics, Ltd. announced an agreement with Pure MHC, an Emergent Technologies portfolio company, for development of a novel assay for quality control that will be an important component of ImmunoCellular's ICT-107 phase 3 registrational clinical program in newly diagnosed glioblastoma, anticipated to begin in the second half of 2015. [More]
Scientists reveal new combination method that efficiently destroys cancer cells

Scientists reveal new combination method that efficiently destroys cancer cells

Scientists at the Institut Pasteur and Inserm have successfully increased the infiltration of immune cells into tumors, thus inducing the immune system to block tumor growth. In an article published in Nature Immunology, the scientists show that, in combination with existing immunotherapies, this process efficiently destroys cancer cells. [More]
Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Weill Cornell scientists reveal how XBP1 gene can trigger immune responses against ovarian tumors

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor, Weill Cornell Medical College scientists report today. But a therapy that restores the cells' disease-fighting abilities could provide a powerful new strategy to attack the cancer, which kills more than 14,000 women each year. [More]
Study reveals how immune cells are programmed to repair or protect the body

Study reveals how immune cells are programmed to repair or protect the body

An unexpected finding by an international team of scientists based at The University of Manchester and National Institutes of Health in America has shed new light on how immune cells are programmed to either repair or protect the body. [More]
New research shows how human immune system could be manipulated to better fight disease

New research shows how human immune system could be manipulated to better fight disease

New research from Australian and Singaporean scientists has revealed how immune cell 'spies' are created, providing clues on how the immune system could be manipulated to better fight disease. [More]
BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife reports increased use of CryoStor and HypoThermosol biopreservation media products in clinical studies

BioLife Solutions, Inc., a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers, today reported several new customer disclosures on the use of the Company's CryoStor and HypoThermosol biopreservation media products in pre-clinical validation projects and clinical trials at the recent International Society for Cellular Therapy (ISCT) conference. [More]
NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors. [More]
FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

FDA clears ADXS-HPV plus epacadostat IND for HPV-associated cervical cancer Phase 2 study

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, today announced the clearance of the Investigational New Drug application by the United States Food and Drug Administration to conduct a Phase 2 study of ADXS-HPV (ADXS11-001) alone or in combination with Incyte Corporation's investigational oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), for the treatment of Stage I-IIIb human papillomavirus (HPV)-associated cervical cancer. [More]
Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias reports positive data from AST-VAC1 Phase 2 trial for intermediate, high risk AML

Asterias Biotherapeutics, Inc., a biotechnology company focused on the emerging field of regenerative medicine, today announced positive, new, long-term follow-up data from a Phase 2 clinical trial of AST-VAC1 in patients with intermediate and high risk acute myelogenous leukemia (AML). [More]
Scientists discover new way to control inflammation during worm infections and allergies

Scientists discover new way to control inflammation during worm infections and allergies

Research from The University of Manchester is bringing scientists a step closer to developing new therapies for controlling the body's response to allergies and parasitic worm infections. [More]
UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

The University of New Mexico Cancer Center recently enrolled its first patient in a phase 3 international clinical trial to test a personalized vaccine against metastatic kidney cancer. Kidney cancer has proven particularly difficult to treat with chemotherapy, and numerous attempts to create a kidney cancer vaccine have not improved survival rates. [More]
Personalized cancer vaccines can be used to marshal powerful immune response

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis. [More]
Advertisement
Advertisement